Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Símbolo de cotizaciónNTRA
Nombre de la empresaNatera Inc
Fecha de salida a bolsaJul 02, 2015
Director ejecutivoMr. Steven Leonard (Steve) Chapman
Número de empleados4424
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 02
Dirección13011 Mccallen Pass
CiudadAUSTIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal78753
Teléfono16502499090
Sitio Webhttps://www.natera.com/
Símbolo de cotizaciónNTRA
Fecha de salida a bolsaJul 02, 2015
Director ejecutivoMr. Steven Leonard (Steve) Chapman
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos